• Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
Wednesday, February 1, 2023
No Result
View All Result
SUBSCRIBE
The Outlooker
27 °c
Delhi
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
No Result
View All Result
The Outlooker
No Result
View All Result
  • National
  • Politics
  • Opinion
  • Business
  • Science
  • World
  • Health
Home Business

Analyst Corner: Maintain ‘add’ on GSK Pharma with TP of Rs 1,613

by The Outlooker Web Desk
May 22, 2021
in Business
0
Analyst Corner: Maintain ‘add’ on GSK Pharma with TP of Rs 1,613
1.8k
SHARES
12.9k
VIEWS
Share on FacebookShare on Twitter

Lower employee and S,G&A expenses cushioned the drop in Ebitda margin to 140 bps y-o-y.

Inline performance: Revenue grew 4.9% y-o-y during the quarter as acute therapies witnessed recovery with falling Covid-19 cases. Although, recent surge in cases may have some near term pressures we expect recovery in the growth to continue with traction in key brands supported by healthy growth in recently launched products (Fluarix Tetra and Menveo) especially with the ongoing vaccination. Gross margin dropped 540 bps y-o-y on a very high base of last year but it was largely stable sequentially. Lower employee and S,G&A expenses cushioned the drop in Ebitda margin to 140 bps y-o-y.

Company has impaired Vemgal by Rs 1.19 billion to reflect the estimated realisable value of Rs 1.8 billion at which it is being sold to Hetero. Hence, reported PAT declined 89.6% y-o-y. Adjusting for it PAT fell 20.0% y-o-y to Rs 1.0 billion.

Key products performance: As per AIOCD data, GSKP has reported a flattish y-o-y performance. T-Bact, Betnovate N and Betnovate C have reported healthy y-o-y growth of 30.5%, 41.3% and 34.9%, respectively for the quarter. However, Augmentin, Synflorix, Calpol and Betnesol have reported a y-o-y decline of 16.9%, 25.6%, 16.3% and 3.5%, respectively. Infanrix Hexa continues its strong momentum with 10.1% y-o-y growth. Fluarix Tetra and Menveo are tracking well with revenue of Rs 19 million and Rs 61 million, respectively during the quarter.

Outlook: While FY21 performance would optically appear muted, its due to Zinteac (ranitidine) sales in the base. However, we expect FY22 to report a strong growth both on revenue and earnings front. We expect 10.1% revenue and 24.2% PAT CAGR over FY21-FY23E driven by growth in power brands, traction in newly launched products and recovery in key therapies like vaccines, respiratory and VMN. Minimal capex requirement would aid cashflow generation of ~Rs16bn over the next two years.

Valuations and risks: We largely maintain our revenue estimates but raise our EPS estimates by 2-3% for FY22E-FY23E to factor in higher other income. Maintain ADD with a revised target price of Rs1,613/share based on 40xFY23E earnings (earlier: Rs1,575/share). Key downside risks: addition of key drugs in NLEM, product concentration.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

The Outlooker is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

The Outlooker Web Desk

The Outlooker Web Desk

Next Post
COVID-19 Transmission Explained By Children In Health Ministry Video

COVID-19 Transmission Explained By Children In Health Ministry Video

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Delhi Police Rejects Requests For Farmers’ March On November 26, 27
National

Delhi Man Kills Father For Refusing To Give Money For Drugs, Arrested

February 1, 2023
Speeding Ferrari Crashes Into Railing On Mumbai’s Bandra-Worli Sea Link, No One Hurt
National

Woman Hires Couple To Kill Labourer Husband In Maharashtra: Cops

February 1, 2023
UP Teacher Strangled To Death On Camera During Online Class: Police
National

UP Teacher Strangled To Death On Camera During Online Class: Police

February 1, 2023
Ajit Doval’s White House Visit To Boost Ties In “Cutting-Edge Sectors”
National

Ajit Doval’s White House Visit To Boost Ties In “Cutting-Edge Sectors”

February 1, 2023

Connect with us

No Result
View All Result

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020

Category

  • Artistic
  • Business
  • Crypto
  • Design
  • Entertainment
  • Fashion
  • featured
  • Food
  • Gaming
  • Health
  • Human
  • Lifestyle
  • Movie
  • Music
  • National
  • Opinion
  • Politics
  • Science
  • Spaces
  • Sports
  • Tech
  • Travel
  • Uncategorized
  • World

Recent Posts

  • Delhi Man Kills Father For Refusing To Give Money For Drugs, Arrested
  • Woman Hires Couple To Kill Labourer Husband In Maharashtra: Cops
  • UP Teacher Strangled To Death On Camera During Online Class: Police

About Us

The Outlooker

The Outlooker is your source of authentic, hand-picked news, stories, analysis from India & the World.

  • Terms Of Service
  • Privacy Policy
  • About us
  • Submit your story
  • Contact

© 2019-2021 The Outlooker. All rights reserved.

No Result
View All Result
  • Home
  • Politics
  • World
  • Business
  • Science
  • National
  • Entertainment
  • Gaming
  • Movie
  • Music
  • Sports
  • Fashion
  • Lifestyle
  • Travel
  • Tech
  • Health
  • Food

© 2019-2021 The Outlooker. All rights reserved.